$NMRA·8-K

Neumora Therapeutics, Inc. · May 29, 4:05 PM ET

Compare

Neumora Therapeutics, Inc. 8-K

Research Summary

AI-generated summary

Updated

Neumora Therapeutics Reports 2026 Annual Meeting Voting Results

What Happened Neumora Therapeutics, Inc. filed an 8-K reporting the results of its Annual Meeting of Stockholders held on May 27, 2026 (record date: April 7, 2026). As of the record date there were 182,688,076 shares outstanding and entitled to vote. Stockholders elected three Class III directors, ratified Ernst & Young LLP as the company’s independent auditor for 2026, and voted on advisory (non-binding) proposals regarding executive compensation and the frequency of such votes.

Key Details

  • Meeting date and record date: Annual Meeting on May 27, 2026; record date April 7, 2026; 182,688,076 shares outstanding.
  • Director elections (Class III, terms to 2029):
    • Paul L. Berns — For: 126,617,746; Withheld: 6,076,577; Broker non-votes: 25,026,919.
    • Matthew Fust — For: 125,242,046; Withheld: 7,452,277; Broker non-votes: 25,026,919.
    • David Piacquad — For: 126,878,899; Withheld: 5,815,424; Broker non-votes: 25,026,919.
  • Auditor ratification: Ernst & Young LLP ratified — For: 157,623,815; Against: 53,613; Abstentions: 43,814. (No broker non-votes.)
  • Executive compensation (advisory “say-on-pay”): For: 131,998,871; Against: 420,917; Abstentions: 274,535; Broker non-votes: 25,026,919.
  • Advisory vote on frequency of future say-on-pay votes: One year selected — One Year: 124,682,414; Two Years: 23,968; Three Years: 7,948,592; Abstentions: 39,349; Broker non-votes: 25,026,919. The Board will hold advisory votes on executive compensation annually.

Why It Matters These results confirm the company’s board makeup for the Class III seats through the 2029 annual meeting and show strong shareholder support for the company’s auditor and its executive compensation program. The annual advisory vote on pay (and the shareholder choice for annual frequency) is non-binding but signals shareholder sentiment on management pay practices; the company will continue to present say‑on‑pay annually. Investors tracking governance and board composition, auditor oversight, or shareholder views on compensation should note these outcomes and the vote totals.

Loading document...